deltatrials
Unknown PHASE1/PHASE2 NCT00807196

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma

Sponsor: Bayer

Conditions Non-Hodgkins Lymphoma
Interventions 90Y ibritumomab tiuxetan (Zevalin) Cyclophosphamide Fludarabine Non myeloablative allogeneic stem cell transplantation Rituximab
Updated 4 times since 2017 Last updated: Dec 10, 2008 Started: Sep 30, 2008 Primary completion: Dec 31, 2011 Completion: Dec 31, 2012

A PHASE1/PHASE2 clinical study on Non-Hodgkins Lymphoma, this trial is ongoing. The trial is conducted by Bayer and has accumulated 4 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

  4. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE1_PHASE2

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Maisonneuve-Rosemont Hospital
Data source: Maisonneuve-Rosemont Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Montreal, Canada